Dr. Hoos Describes Ipilimumab and Future Immunotherapies

Axel Hoos, MD, PhD
Published: Wednesday, Jul 13, 2011

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses ipilimumab (Yervoy) and how it is a first-in-class agent that enhances activation of T cells. He elaborates that Bristol-Myers Squibb plans to build upon this success with their new drug the anti-PD-1 agent MDX-1106.
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses ipilimumab (Yervoy) and how it is a first-in-class agent that enhances activation of T cells. He elaborates that Bristol-Myers Squibb plans to build upon this success with their new drug the anti-PD-1 agent MDX-1106.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x